Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lipocine Inc (LPCN)

Lipocine Inc (LPCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Lipocine: Q2 Earnings Snapshot

Lipocine: Q2 Earnings Snapshot

LPCN : 4.64 (-2.11%)
Lipocine: Q1 Earnings Snapshot

Lipocine: Q1 Earnings Snapshot

LPCN : 4.64 (-2.11%)
Lipocine: Q3 Earnings Snapshot

Lipocine: Q3 Earnings Snapshot

LPCN : 4.64 (-2.11%)
Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr....

LPCN : 4.64 (-2.11%)
Lipocine: Q2 Earnings Snapshot

Lipocine: Q2 Earnings Snapshot

LPCN : 4.64 (-2.11%)
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced financial...

LPCN : 4.64 (-2.11%)
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...

LPCN : 4.64 (-2.11%)
Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...

LPCN : 4.64 (-2.11%)
Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its...

LPCN : 4.64 (-2.11%)
Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), today announced positive topline results from a pilot clinical PK bridge study of LPCN 1154 (oral brexanolone)...

LPCN : 4.64 (-2.11%)

Barchart Exclusives

Will OJ Continue to Make New Highs?
Frozen concentrated orange juice is one of the five soft commodities. FCOJ has the distinction as the most illiquid, meaning it suffers from the lowest volume and open interest. Like many soft commodities, FCOJ has been on a bullish run, but unlike the others, it reached a new record high in September 2024. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar